GLP-1 Agonists Show Promise Even in HFrEF: Mortality and CV Benefit Signal

A meta-analysis of patients with type 2 diabetes and heart failure with reduced ejection fraction reported that GLP-1 receptor agonist therapy was associated with lower all-cause mortality and fewer major cardiovascular events over approximately five years of follow-up. Benefits appeared additive to standard heart failure therapies, suggesting GLP-1RAs may be underused in this high-risk group. The analysis reinforces guideline moves toward integrating cardioprotective glucose-lowering agents into routine HF–diabetes co-management. To learn more Click Here ##Reference## Vignarajah A, Oro P, El Dahdah J, Vigneswaramoorthy N, Vest AR, Shah G.

All-cause mortality and cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and heart failure with reduced ejection fraction. Am Heart J Plus. 2025;60:100676.## In your experience, what most limits…